Stockreport

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Clearside Biomedical, Inc.  (CLSD) 
Last clearside biomedical, inc. earnings: 3/11 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.clearsidebio.com/investor-overview
PDF - ARCATUS®, Branded as XIPERE® in the U.S., is the First Globally Approved Suprachoroidal Therapy - - Continued Global Expansion of Clearside’s Suprachoroidal Space [Read more]